Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is currently conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease.’ The study aims to demonstrate that maridebart cafraglutide is superior to a placebo in achieving a significant reduction in body weight among participants with obesity.
The intervention being tested is maridebart cafraglutide, a drug administered subcutaneously in varying doses, designed to promote weight loss in individuals with obesity.
This interventional study employs a randomized, parallel assignment model with double masking, involving both participants and investigators. The primary purpose of the study is treatment-focused, aiming to assess the drug’s effectiveness in reducing body weight.
The study began on June 13, 2025, with the latest update submitted on June 24, 2025. These dates are crucial as they mark the commencement of participant recruitment and the most recent information update, respectively.
The outcome of this study could significantly impact Amgen’s stock performance, as successful results may enhance investor confidence and position the company favorably against competitors in the obesity treatment market. The ongoing recruitment phase indicates potential future developments that investors should monitor closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.